Drug Database
Back to search

Netherlands· NL-07af4f68cdeb

Lariam, tabletten 250 mg

A mefloquine product containing mefloquinehydrochloride, registered in Netherlands by Euro Registratie Collectief B.V.. The same ATC class is registered in 9 of our 19 countries.

ATC P01BC02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedLariam, tabletten 250 mgATCP01BC02REGISTER NO.NL-07af4f68cdebPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about mefloquinehydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Mefloquine is registered in 9 of 19 countries.

Countries holding a registration under ATC P01BC02 (mefloquine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 5 of them publish a price we can compare per daily dose
Search mefloquine products by name

Mefloquine · ATC P01BC02

9 / 19 countries

  • Belgiumprice
  • Canada
  • Finlandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
MEFLOQUINEHYDROCHLORIDE
Manufacturer
Euro Registratie Collectief B.V.
Country
Netherlands (NL)
ATC code
P01BC02
ATC class
Mefloquine
Defined daily dose
1 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    109318//11154

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

439 interactions on record for mefloquine.

Graded by severity as the source publishes them — 82 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check mefloquine against other medicinesHow interaction checks work

Mefloquine · interactions on record

439 records

  • 82 severe
  • 338 moderate
  • 8 minor
  • 11 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • ProcainamideC01BA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Mefloquine in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mefloquine products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Austria · Lariam
  • Belgium · Lariam
  • Cyprus · Eloquine
  • Finland · Lariam
  • France · Lariam
  • United Kingdom (Northern Ireland) · Lariam, Mefloquine
  • Italy · Lariam
  • Luxembourg · Lariam
  • Norway · Lariam
  • Portugal · Mephaquin Lactab
  • Sweden · Lariam

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fe3232f9-1bd0-4401-a3e0-1a47ae8cd8ce
GET /v1/drugs/fe3232f9-1bd0-4401-a3e0-1a47ae8cd8ce?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h11154_smpc.pdf",
  "strength": null,
  "atc_label": "Mefloquine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg109318",
  "excipients": [
    "AMMONIUM CALCIUM ALGINAAT",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSPOVIDON (E 1202)",
    "LACTOSE 0-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MAÏSZETMEEL",
    "POLOXAMEER",
    "TALK (E 553b)"
  ],
  "substances": [
    "MEFLOQUINEHYDROCHLORIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h109318.pdf",
  "authorised_at": "2011/02/23",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "109318//11154",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about mefloquine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console